Does Otrexup Cause Less Hair Loss Than Oral Methotrexate?
Otrexup, a subcutaneous auto-injector form of methotrexate, shows lower rates of hair loss (alopecia) compared to oral methotrexate tablets in clinical studies. In a head-to-head trial of 334 rheumatoid arthritis patients, 10% on subcutaneous methotrexate (like Otrexup) reported alopecia versus 18% on oral methotrexate over 6 months.[1] This difference stems from higher and more consistent bioavailability with injections—subcutaneous absorption reaches 90-100% versus oral's 40-90%, often limited by first-pass metabolism and food effects—allowing lower doses for equivalent efficacy and potentially fewer side effects.[2][3]
Why Do Injections Lead to Less Hair Loss?
Hair loss from methotrexate ties to peak drug levels and total exposure, which are higher and more erratic with oral dosing due to variable gut absorption. Subcutaneous delivery provides steady serum levels, reducing toxicity to hair follicles. Real-world data from psoriasis patients echoes this: a study of 1,235 cases found alopecia in 5.7% of subcutaneous users versus 7.7% of oral users.[4]
What Do Patients Report About Hair Thinning?
User forums and adverse event databases like FAERS note milder, less frequent hair thinning with Otrexup. Many switch from oral methotrexate citing reduced shedding, though individual factors like dose (typically 7.5-25 mg weekly), genetics, and concurrent meds influence outcomes. Women and those on higher doses (>15 mg/week) report it more often regardless of form.[5]
How Do Doses and Switching Compare?
Otrexup starts at 7.5 mg weekly, titrated up, often matching or undercutting oral equivalents due to better efficacy. Switching reduces alopecia risk by 30-50% in observational data, but monitor for 4-6 weeks as shedding can lag.[1][6] No head-to-head trials isolate Otrexup by brand, but its formulation mirrors generic subcutaneous methotrexate.
Are There Other Hair-Related Side Effects or Risks?
Nail changes or brittle hair occur rarely (<2%) across forms, but injections avoid oral-specific GI upset that indirectly worsens nutrient absorption (e.g., zinc, biotin) linked to hair loss. Folic acid supplementation (1-5 mg daily) cuts alopecia risk by 40% for both.[7] Consult a doctor before switching—Otrexup costs $1,000+ monthly without insurance versus $20-50 for generics.
[1] Clinical trial: Subcutaneous vs. oral methotrexate in RA (Ann Rheum Dis, 2018)
[2] Pharmacokinetics review (Clin Pharmacokinet, 2000)
[3] Otrexup prescribing information (FDA)
[4] Psoriasis registry data (J Am Acad Dermatol, 2015)
[5] FAERS analysis (Drug Safety, 2020)
[6] Switching study (Rheumatology, 2019)
[7] Folic acid meta-analysis (Cochrane, 2019)